Inhibition of Rat Mammary Gland Carcinogenesis by Simultaneous Targeting of Cyclooxygenase-2 and Peroxisome Proliferator-activated Receptor γ
Authors:
Open Access
- 1 February 2004
- journal article
- retracted article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (3) , 1181-1189
Abstract
We examined the effect of celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, and N-(9-fluorenyl-methyloxycarbonyl)-l-leucine (F-l-Leu), a peroxisome proliferator-activated receptor γ (PPARγ) agonist, separately and combined, on the development of methylnitrosourea (MNU)-induced rat mammary gland carcinogenesis. Celecoxib and F-l-Leu significantly reduced tumor incidence and multiplicity (P < 0.05). Combining both agents exerted higher (synergistic) cancer inhibition than separate treatments (P < 0.05). The effects of the test drugs on COX-2 and PPARγ expression and on the synthesis of prostaglandin E2 (PGE2) and 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2) were examined in rat mammary normal (MNU-untreated), uninvolved, and tumor (MNU-treated) tissues. Celecoxib and F-l-Leu, separately, inhibited COX-2 and up-regulated PPARγ expression. These effects were paralleled by inhibition of PGE2 synthesis and up-regulation of 15d-PGJ2. Combined treatment resulted in higher alterations in COX-2 and PPARγ transcripts and PG synthesis compared with separate administrations. The effect of the test agents on Bcl2, BAX, and protein kinase Cα expression levels were examined in the rat mammary gland and the pro-(BAX:Bcl2) and anti-[PKCα*(Bcl2/BAX)] apoptotic ratios were evaluated. Each drug increased the proapoptotic ratio by 2- to 7-fold and reduced the antiapoptotic ratio by 2- to >8-fold in all tissues. Combined treatment, however, resulted in >9- to 14-fold up-regulation in the proapoptotic processes and 15- to >30-fold down-regulation in the antiapoptotic ones. Analyses were also carried out on the drug-induced modulation of cell cycle regulators and proliferation markers (cyclin-dependent kinase 1 and proliferating cell nuclear antigen). F-l-Leu and celecoxib each reduced the cyclin-dependent kinase 1 and proliferating cell nuclear antigen expression in the tumor. Higher down-regulation was attained in all tissues by combined treatment where cyclin-dependent kinase 1 and proliferating cell nuclear antigen almost retained the expression levels observed in the normal glands. In conclusion, simultaneous targeting of COX-2 and PPARγ may inhibit mammary cancer development more effectively than targeting each molecule alone. COX-2 inhibitors and PPARγ agonists coordinately mediate their anticancer effect via both COX-dependent (inhibition of COX-2, activation of PPARγ, and modulation PG synthesis) and COX-independent (induction of proapoptotic factors and inhibition of cell proliferation) pathways.Keywords
This publication has 63 references indexed in Scilit:
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinomaCancer, 2002
- Expression profiling of gastric adenocarcinoma using cDNA arrayInternational Journal of Cancer, 2001
- Mesalazine Changes Apoptosis and Proliferation in Normal Mucosa of Patients with Sporadic Polyps of the Large BowelEndoscopy, 2000
- Expression of Peroxisome Proliferator Activated Receptor mRNA in Normal and Tumorigenic Rodent Mammary GlandsBiochemical and Biophysical Research Communications, 1998
- Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosoureaCarcinogenesis, 1995
- Apoptosis in the Pathogenesis and Treatment of DiseaseScience, 1995
- Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature, 1990
- Gene expression of PCNA/cyclin in adult tissues and the R3230AC mammary tumor of ratBiochemical and Biophysical Research Communications, 1989
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976